Detalhe da pesquisa
1.
Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
HIV Clin Trials
; 14(3): 99-109, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835512
2.
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.
HIV Clin Trials
; 14(4): 149-59, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924587
3.
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
J Pharmacokinet Pharmacodyn
; 38(1): 41-61, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21088872
4.
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.
Br J Clin Pharmacol
; 68(3): 355-69, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19740392
5.
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Br J Clin Pharmacol
; 65 Suppl 1: 76-85, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18333869
6.
Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.
Clin Transl Sci
; 11(1): 54-62, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29106053
7.
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Antivir Chem Chemother
; 27: 2040206619895706, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856576
8.
Single-dose pharmacokinetics, safety, and tolerability of modified-release formulations of lersivirine in healthy subjects.
Clin Pharmacol Drug Dev
; 3(6): 472-6, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27129121